Skip to main content

Dr. Katrina Y. Glover, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
29
In the NPI registry since
2006
Medicare patients seen, 2024
365

Licensed in Texas since 2004, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1997Medical school: University of Texas Southwestern Medical School at Dallas
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    TX license M0091 (first issued 2004; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
365
Services billed
1,142
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes432158
Established patient office or other outpatient visit, 30-39 minutes181104
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes12341
Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month8816
New patient office or other outpatient visit, 60-74 minutes4242
Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month3913
Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional3412
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes3325
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes2423

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 25 companies reported 58 payments worth $3,029 in total to this clinician.

By company
AstraZeneca Pharmaceuticals LP$1,931
AbbVie Inc.$233
E.r. Squibb & Sons, L.l.c.$101
Tempus Ai, Inc$100
GlaxoSmithKline, LLC.$93.75
Novartis Pharmaceuticals Corporation$58.35
Array Biopharma Inc$47.16
Geron Corporation$44.46
By type
Consulting Fee$1,675
Food and Beverage$1,330
Education$23.10

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
May 22, 2025AstraZeneca Pharmaceuticals LP
May 22, 2025
Consulting Fee
IMFINZI · Oncology
$1,675
Jun 17, 2025AstraZeneca Pharmaceuticals LP
Jun 17, 2025
Education
in-kind
Company’s descriptionJournal Article
$23.10

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $30,414 in research payments for these studies, mostly to the institutions running them.

  • A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Ch…
    Janssen Research & Development, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Tyler

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 18, 2019), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1144248501. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.